ArticleJACC. Case reports2026
Atypical Presentations of Coronary Microvascular Dysfunction in Patients After COVID.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coronary microvascular function in patients with sepsis and myocardial injury: an invasive coronary physiology study.Critical care (London, England) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary microvascular dysfunction is a recognized cause of angina without obstructive coronary disease, yet routine tests are often nondiagnostic. In this case series, we describe 3 previously active adults with persistent chest pain after SARS-CoV-2 infection who fulfilled the World Health Organization criteria for postacute sequelae. All 3 patients underwent invasive coronary angiography with coronary reactivity testing with coronary flow reserve (CFR). In all patients, the epicardial coronary arteries were angiographically normal, however CFR was significantly impaired (<2.0). Medical management was tailored and guideline-concordant, including the use of calcium-channel blockers, beta-blockers, long-acting nitrates, and graded exercise, with some improvement in symptoms. We contend that coronary microvascular dysfunction may be the etiology of post-COVID chest pain. An earlier CFR assessment may shorten diagnostic delays and improve quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.